ONE DROP 24-hour ocular allergy itch relief with co-pay savings                                                                                                                                                                                                          
To view this email as a web page, go here.

This communication is from Ophthalmology Times, developed under the direction and sponsorship of Novartis Pharmaceuticals Corporation.


ONE DROP 24-hour ocular allergy itch relief with co-pay savings
Full Prescribing Information
Important Safety Information

View as website

• PAZEO® Solution: the ONLY FDA-approved therapy with demonstrated 24-hour ocular allergy itch relief in ONE DROP1

• PAZEO® Solution: has the highest concentration of olopatadine available on the market1-3
_Three solubilizing excipients maintain a neutral pH4

• No generic therapeutic equivalent is available5

• The most commonly reported adverse reactions occurred in 2-5% of patients treated with either PAZEO® Solution: or vehicle. These events were blurred vision, dry eye, supercial punctate keratitis, dysgeusia, and abnormal sensation in eye1.

Please see Important Safety Information
iKey

Help your patients save on their co-pay for PAZEO® Solution
Your eligible commercially insured patients may pay a co-pay of as little as $10 with the Co-Pay Savings Card!
•Limitations apply*
INDICATION AND DOSING

PAZEO® Solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis. The recommended dosage is to instill one drop in each affected eye once a day.

IMPORTANT SAFETY INFORMATION

As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle to prevent contaminating the tip and solution. Keep bottle tightly closed when not in use.

Patients should not wear a contact lens if their eye is red. PAZEO® Solution should not be used to treat contact lens-related irritation. The preservative in PAZEO® Solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least five minutes after instilling PAZEO® Solution before they insert their contact lenses.

The most commonly reported adverse reactions in a clinical study occurred in 2%-5% of patients treated with either PAZEO® Solution or vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia, and abnormal sensation in eye1 .

For additional information on PAZEO® Solution, please click here to view the full Prescribing Information.

*Terms and Conditions:

Limitations apply. For commercially insured patients. Up to a $125 cap per bottle. Patient will be responsible for any co-pay once limit per bottle is reached. This offer is not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients. Novartis reserves the right to rescind, revoke, or amend this program without notice. Offer expires [12/31/2017].

For more information about PAZEO® Solution, visit www.pazeohcp.com.

References:
1. PAZEO [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2016. 2. PATADAY [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2010. 3. PATANOL [package insert]. Fort Worth, TX: Alcon Laboratories, Inc; 2007. 4. Data on file, 2012. 5. US Department of Health and Human Services. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. In: The Orange Book. 36th ed. Rockville, MD: US Department of Health and Human Services; 2016.

Olopatadine is licensed from Kyowa Hakko Kirin Co., Ltd. Japan

©2017 Novartis 4/17 T-PAL-1341697

Full Prescribing Information


You received this e-mail because you are a customer of Ophthalmology Times, a UBM publication. You are on the mailing list as clem.natale@ubm.com

To ensure delivery to your Inbox, please add us to your address book.

From time to time, we will inform customers of latest offers and new products from relevant business partners. If you do not wish to receive this type of information, click here.

If you would like to contact us by phone, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-7223. Outside the U.S., please phone 1-218-740-6895.

Ophthalmology Times, a UBM publication
131 W. 1st Street
Duluth, MN 55802-2065 USA.
Privacy Policy